Related Articles
Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Difference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitant
A phase II clinical trial of palonosetron for the management of delayed vomiting in gynecological cancer patients receiving paclitaxel/carboplatin therapy
Comparison between the antiemetic effects of palonosetron and granisetron in breast cancer patients treated with anthracycline‑based regimens
Palonosetron exhibits higher total control rate compared to first‑generation serotonin antagonists and improves appetite in delayed‑phase chemotherapy‑induced nausea and vomiting